Table 1.
Demographics of the study groups
| Urine set (n = 90) | Tissue set (n = 30) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Training set (n = 38) | Validation set (n = 52) | |||||||||
| Pre-treatment (n = 13) | Remission (n = 13) | Relapse (n = 12) | P | HC (n = 13) | Pre-treatment (n = 13) | Remission (n = 13) | Relapse (n = 13) | P | Tumor/adjacent normal pairs (n = 30) | |
| Age | 61.8 ± 10.8 | 63.6 ± 10.7 | 59.2 ± 9.9 | P = 0.83 | 69.1 ± 4.5 | 69.1 ± 5.9 | 66.8 ± 9.1 | 65.0 ± 8.4 | P = 0.64 | 65.3 ± 10.6 |
| Gender | ||||||||||
| Male | 13 (100%) | 13 (100%) | 12 (100%) | 10 (100%) | 19 (100%) | 8 (100%) | 8 (100%) | 30 (100%) | ||
| Smoking habit | ||||||||||
| Nonsmoker | 3 (23%) | 3 (23%) | 3 (25%) | P = 1.00 | 3 (30%) | 2 (22%) | 2 (25%) | 2 (25%) | P = 0.99 | 5 (17%) |
| Ever smoker | 10 (77%) | 10 (77%) | 9 (75%) | 7 (70%) | 7 (78%) | 6 (75%) | 6 (75%) | 25 (83%) | ||
| Clinical stage | ||||||||||
| Limited stage | 2 (15%) | 2 (15%) | 2 (17%) | P = 1.00 | 2 (22%) | 2 (25%) | 1 (13%) | P = 0.84 | 30 (100%) | |
| Extended stage | 11 (85%) | 11 (85%) | 10 (83%) | 7 (78%) | 6 (75%) | 7 (88%) | 0 (0%) | |||
| ECOG | ||||||||||
| 0–1 | 10 (77%) | 11 (85%) | 9 (75%) | P = 0.86 | 8 (89%) | 7 (88%) | 6 (75%) | P = 0.74 | 30 (100%) | |
| ≥ 2 | 3 (23%) | 2 (15%) | 3 (25%) | 1 (11%) | 1 (13%) | 2 (25%) | 0 (0%) | |||
| NSE (μ/L) | 41.48 (32.81 ~ 88.22) | 10.67 (9.68 ~ 14.69) | 24.20 (15.43 ~ 87.79) | P = 0.0007 | 13.31 ± 3.8 | 33.45 (22.34 ~ 96.98) | 10.23 (8.29 ~ 18.84) | 18.29 (12.65 ~ 29.73) | P = 0.0068 | 35.67 (24.82 ~ 83.45) |